Richmond promotes new Director of Communications and Participant Engagement

London, 7 August 2024 - Richmond Pharmacology is delighted to announce the promotion of Liz Romano to the new position of Director of Communications and Participant Engagement. The position has been created to support Richmond’s strategic ambitions and communications and its commitment to enhancing engagement with participants in its clinical trials.

Liz joined Richmond Pharmacology over two years ago as Head of Marketing and has since made significant contributions to the company. Her innovative approach, vision, and commitment to excellence have been instrumental in strengthening Richmond’s communication and marketing efforts and among her many achievements has been her recent delivery of a complete company rebrand.

In this new role, Liz will continue to lead and oversee all aspects of Richmond’s communication and marketing strategies. In addition, Liz will manage the teams dedicated to attracting, enrolling, and retaining participants for clinical studies – critical to the success and feasibility of Richmond’s trials. - while technical oversight is provided by the company’s co-founders Dr Jorg Taubel and Dr Ulrike Lorch.

Prior to joining Richmond, Liz has had a broad marketing experience spanning over 20 years, including working in a variety of industries from financial services and a not-for-profit leisure trust to engineering and construction and hospitality and tourism.

Liz commented on her new role: "I am deeply honoured to take on the role of Director of Communications and Participant Engagement at Richmond Pharmacology. Over the past two years, I have witnessed firsthand the dedication and innovation that drives our team. I am excited to continue working closely with our participants and to further enhance our communication strategies, ensuring that Richmond remains at the forefront of clinical trial excellence. Our participants are central to everything we do, and I look forward to leading efforts to engage, support, and retain them throughout their journey with us."

-Ends-

Notes to Editor:

About Richmond

Richmond is a leading UK CRO, founded in 2001, specialising in first-in-human studies and adaptive clinical trials for gene editing and gene silencing therapies. In 2021 it was first in the world to treat a patient with the Nobel Prize-winning CRISPR-cas9 gene editing tool and currently has more patients undergoing cutting-edge genetic trials than any other clinic in the world. It has completed more than 500 early phase studies and helped deliver 30 medicines to market - including drugs for heart failure, hypertension and cancer. Clients include top 10 pharma, genetic engineering and biotech companies from around the world, especially Europe, the USA and Japan. In 2020, Richmond founded the Richmond Research Institute to advance understanding of under-researched diseases.

For more information, please contact Linda Rose: linda@denhams.digital 07788 592842